Document is current
Any future updates will be listed below
-
Authors
Evans, Andrew K.
Park, Heui Hye
Woods, Claire E.
Lam, Rachel K.
Rijsketic, Daniel Ryskamp
Xu, Christine
Chu, Emily K.
Ciari, Peter
Blumenfeld, Sarah
Vidano, Laura M.
Saw, Nay Lui
Heifets, Boris D.
Shamloo, Mehrdad
-
Funding
Funding for this research was provided by:
NIH (R21 NS097945, R21 NS097945, R21 NS097945, R21 NS097945, R01 AG054533, R21 NS097945, R21 NS097945, R01 AG054533, R01 AG054533, R01 AG054533, R21 NS097945, R01 MH130591, R21 NS097945)
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 19 November 2024
First Online: 18 December 2024
Declarations
:
: Not applicable.
: Not applicable.
: MS is a shareholder and founder of CuraSen Therapeutics, a company developing adrenergic drugs for the treatment of neurodegenerative disease. AKE is a shareholder of CuraSen Therapeutics. However, this work was initiated and carried out independently from CuraSen Therapeutics and was not designed, initiated, or funded by CuraSen Therapeutics. BDH is on the scientific advisory boards of Journey Clinical and Osmind, and is a paid consultant to Arcadia Medicine, Inc.
